{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-002689","form_type":"8-K","ticker":"GRCE","cik":"0001444192","company_name":"Grace Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.211464+00:00","generated_at":"2026-06-07T02:10:05.447494+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Acasti Pharma appoints Robert J. DelAversano as principal financial and accounting officer, effective Jan 5, 2024","bullets":["Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.","Brian Ford removed as interim-CFO; remains as financial consultant on an as-needed basis.","DelAversano receives $290,000 base salary, up to 30% target bonus, and 42,000 stock options at $2.125 per share.","DelAversano joined Acasti in Nov 2023; prior experience at OncoSec and Brio Financial Group."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-002689","json":"https://secwatch.observer/filing/0000950170-24-002689.json","markdown":"https://secwatch.observer/filing/0000950170-24-002689.md","text":"https://secwatch.observer/filing/0000950170-24-002689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/acst-20240105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:10:05.447494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"896bb99371","claim":"Brian Ford was removed as Interim Chief Financial Officer at Grace Therapeutics, Inc..","evidence_excerpt":"Concurrently with such appointment, the Board removed Brian Ford from the position of interim-Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"removed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"d3ef46120a","claim":"Robert J. DelAversano was appointed as Principal Financial Officer and Principal Accounting Officer at Grace Therapeutics, Inc..","evidence_excerpt":"On January 5, 2024, the Board of Directors (the “Board”) of Acasti Pharma Inc. (the “Company”) approved the appointment of Robert J. DelAversano, the Company's Vice President, Finance, to the roles of principal financial officer and principal accounting officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1444192/000095017024002689/0000950170-24-002689-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Financial Officer and Principal Accounting Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}